home / stock / prfx / prfx news

PRFX News and Press, PainReform Ltd. From 04/09/24

Stock Information
Company Name: PainReform Ltd.
Stock Symbol: PRFX
Market: NASDAQ
Website: painreform.com
Menu
PRFX PRFX Quote PRFX Short PRFX News PRFX Articles PRFX Message Board
Get PRFX Alerts

News, Short Squeeze, Breakout and More Instantly...
PRFX - PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced groundbreaking results from new studies ...
PRFX - PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it has reached the 50% enrollme...

PRFX - Expected US Company Earnings on Thursday, March 28th, 2024

Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...

PRFX - Expected US Company Earnings on Thursday, March 21st, 2024

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
PRFX - PainReform Provides Year-End Business Update

Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy Remains on track to announce top-line data by mid- 2024 TEL AVIV, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" P...

PRFX - PainReform to Present at the Microcap Conference in Atlantic City

TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company") , a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at Th...

PRFX - PainReform files to sell 968,545 ordinary shares for holders

2024-01-12 16:22:32 ET More on PainReform Seeking Alpha’s Quant Rating on PainReform Historical earnings data for PainReform Financial information for PainReform For further details see: PainReform files to sell 968,545 ordinary shares for holders
PRFX - PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

TEL AVIV, Israel, Jan. 03, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today reported in vitro test results comparing t...

PRFX - SOS, HUT and BTBT are among pre market gainers

2024-01-02 08:41:15 ET Longboard Pharmaceuticals  ( LBPH ) +172% Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants Signing Day Sports ( SGN ) +32% Collaboration as the Exclusive Recruiti...

PRFX - PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into a definitive agre...
Previous 10 Next 10